HOOD
Robinhood Markets, Inc.
HOOD's fundamentals are mixed, but it looks cheap: trading at 38x earnings, below its usual 51x. Analysts expect strong earnings growth, though they disagree widely on how much.
NMR
Nomura Holdings, Inc.
There isn't enough reported data to score NMR yet.
HOOD Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| N/A | |
| N/A |
HOOD's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like HOOD.
NMR Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Healthy | |
| N/A | |
| N/A |
NMR's profitability is currently healthy. There isn't enough data to rate its revenue. Free cash flow and net leverage aren't meaningful measures for financial services companies like NMR.
HOOD PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 30x | $81.35 | — |
| Cheap | 37x | $78.84 | -3.1% |
| Current | 38x | $81.35 | — |
| Fair | 51x | $110 | +35% |
| Expensive | 74x | $160 | +96% |
Historical ranges are pointers, not guarantees.
HOOD has the edge over NMR in the historical PE scenario, which offers more potential upside but is not a forecast.
NMR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 7.9x | $5.90 | -38% |
| Fair | 12x | $8.70 | -9% |
| Current | 13x | $9.56 | — |
| Expensive | 18x | $13.82 | +45% |
Historical ranges are pointers, not guarantees.
NMR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
HOOD Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Moderate | |
| Low |
HOOD has the edge over NMR on the outlook, with more favorable earnings and profitability expectations.
NMR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| High |
Analysts expect NMR's revenue to grow, but its profitability to weaken.
HOOD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.72 | +26% |
| Q3 2026 | $2.16 | -10% |
| Q2 2026 | $2.26 | +15% |
| Q1 2026 | $2.06 | +18% |
| Q4 2025 | $2.05 | +31% |
| Q3 2025 | $2.40 | +314% |
| Q2 2025 | $1.96 | +513% |
| Q1 2025 | $1.75 | +1150% |
| Q4 2024 | $1.56 | +$2.17 |
HOOD earned $2.16 per share over the past year, down 10% from the year before.
NMR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q1 2026 | $0.75 | +7.1% |
| Q3 2025 | $0.76 | +36% |
| Q1 2025 | $0.70 | +112% |
| Q3 2024 | $0.56 | +107% |
| Q1 2024 | $0.33 | +74% |
| Q3 2023 | $0.27 | +23% |
| Q1 2023 | $0.19 | -32% |
| Q3 2022 | $0.22 | +$0.23 |
NMR has the edge over HOOD in the latest year-over-year earnings comparison.
HOOD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.4B | +12% |
| Q2 2026 | $1.3B | +32% |
| Q1 2026 | $1.1B | +15% |
| Q4 2025 | $1.3B | +27% |
| Q3 2025 | $1.3B | +100% |
| Q2 2025 | $989M | +45% |
| Q1 2025 | $927M | +50% |
| Q4 2024 | $1B | +115% |
HOOD's revenue has grown year over year for 16 quarters in a row: $1.4B last quarter, up 12% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 44% | -5.9 points |
| Q2 2026 | 54% | +9.5 points |
| Q1 2026 | 39% | -1.5 points |
| Q4 2025 | 52% | -3.5 points |
| Q3 2025 | 50% | +26 points |
| Q2 2025 | 45% | +17 points |
| Q1 2025 | 40% | +14 points |
| Q4 2024 | 55% | +49 points |
HOOD's operating margin was 44% last quarter, down 5.9 points from the same quarter a year ago.
NMR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $7.1B | +18% |
| Q3 2025 | $6.5B | +11% |
| Q1 2025 | $6B | +13% |
| Q3 2024 | $5.9B | +31% |
| Q1 2024 | $5.3B | +18% |
| Q3 2023 | $4.5B | +16% |
| Q1 2023 | $4.5B | +3.9% |
| Q3 2022 | $3.9B | -8.2% |
NMR has the edge over HOOD in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2026 | 21% | -0.3 points |
| Q3 2025 | 28% | +14 points |
| Q1 2025 | 25% | +6.3 points |
| Q3 2024 | 25% | +18 points |
| Q1 2024 | 21% | +2.6 points |
| Q3 2023 | 15% | +0.9 points |
| Q1 2023 | 18% | +26 points |
| Q3 2022 | 7.8% | -24 points |
NMR's operating margin was 21% last quarter, about level with the same quarter a year ago.
HOOD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.2B | +$2.8B |
| Q2 2026 | $720M | -79% |
| Q1 2026 | $2B | +217% |
| Q4 2025 | -$937M | +$463M |
| Q3 2025 | -$1.6B | -187% |
| Q2 2025 | $3.5B | +6398% |
| Q1 2025 | $642M | +$1.3B |
| Q4 2024 | -$1.4B | -246% |
HOOD's free cash flow was $3B over the past year, up 159% from the year before. Free cash flow isn't a meaningful measure for financial services companies like HOOD.
NMR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$12.7B | -$10.1B |
| Q3 2025 | $5.2B | +$8B |
| Q1 2025 | -$2.6B | -$1.6B |
| Q3 2024 | -$2.8B | -420% |
| Q1 2024 | -$968.3M | -$27.3M |
| Q3 2023 | $885.9M | +$5.4B |
| Q1 2023 | -$941M | +$6.6B |
| Q3 2022 | -$4.5B | -$2.8B |
NMR's free cash flow was −$12.9B over the past year, against −$5.5B the year before. Free cash flow isn't a meaningful measure for financial services companies like NMR.
HOOD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.1% | -1M shares |
| 1 year | -0.8% | -6.9M shares |
| 3 years | +1.8% | +15.9M shares |
| 5 years | +292% | +679M shares |
| Available history | +7.2% | +60.8M shares |
HOOD has 911M diluted shares, down 0.8% from a year ago, with $789M in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $25M |
| Q2 2026 | $414M |
| Q1 2026 | $250M |
| Q4 2025 | $100M |
| Q3 2025 | $107M |
| Q2 2025 | $124M |
| Q1 2025 | $322M |
| Q4 2024 | $160M |
HOOD spent $789M buying back its own shares over the past year, up 11% from the year before.
NMR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -9.6% | -325M shares |
| 1 year | -14% | -498M shares |
| 3 years | -20% | -781M shares |
NMR has the edge over HOOD on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q1 2026 | $260.1M |
| Q3 2025 | $376.1M |
| Q1 2025 | $50,144 |
| Q3 2024 | $369.8M |
| Q1 2024 | $257.1M |
| Q3 2023 | $125.4M |
| Q1 2023 | $9.5M |
| Q3 2022 | $145.5M |
HOOD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.3x | Net Cash |
| Q2 2026 | -2.1x | Net Cash |
| Q1 2026 | -2.2x | Net Cash |
| Q4 2025 | -1.9x | Net Cash |
| Q3 2025 | -2.1x | Net Cash |
| Q2 2025 | -2.6x | Net Cash |
| Q1 2025 | -3.3x | Net Cash |
| Q4 2024 | -3.8x | Net Cash |
HOOD has more cash than debt. Net leverage isn't a meaningful measure for financial services companies like HOOD.
NMR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | 21.7x | High |
| Q3 2025 | 16.5x | High |
| Q1 2025 | 18.8x | High |
| Q3 2024 | 19.0x | High |
| Q1 2024 | 26.8x | High |
| Q3 2023 | 28.2x | High |
| Q1 2023 | 31.5x | High |
| Q3 2022 | 32.4x | High |
NMR's net debt is more than 20 years of its operating earnings (EBITDA), down from more than 20 years a year ago. Net leverage isn't a meaningful measure for financial services companies like NMR.
HOOD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.8 | Neutral |
| Stochastic | 9.5 | Oversold |
HOOD's weekly RSI is 41 (neutral) and its Stochastic is 10 (oversold).
NMR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 52.8 | Neutral |
| Stochastic | 26.2 | Neutral |
NMR's weekly RSI is 53 (neutral) and its Stochastic is 26 (neutral).
HOOD PE vs Financial Services Sector
| Metric | HOOD | Sector median | Relative |
|---|---|---|---|
| PE | 38x | 13x | 189% above |
| PE % | 22 | 66 | 44 pts below |
HOOD is trading at 38x earnings, a 189% premium to the Financial Services sector's median of 13x.
NMR PE vs Financial Services Sector
| Metric | NMR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 13x | 1.5% below |
| PE % | 59 | 63 | 4 pts below |
NMR has the edge over HOOD on valuation relative to its sector.
HOOD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $97.8 | 17% below |
| 20 week MA | $102.2 | 20% below |
| 50 week MA | $95.4 | 15% below |
| 100 week MA | $88.5 | 8.1% below |
| 200 week MA | $52.1 | 56% above |
HOOD has fallen below most of its moving averages, though it's still 56% above its 200-week average.
NMR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $9.49 | 0.7% above |
| 20 week MA | $9.75 | 1.9% below |
| 50 week MA | $8.94 | 6.9% above |
| 100 week MA | $7.73 | 24% above |
| 200 week MA | $6.28 | 52% above |
NMR has the edge over HOOD on trend strength, trading above more of its moving averages.
HOOD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $35.2 | $18.9 | -46% |
| 2022 | $18.9 | $7.95 | -58% |
| 2023 | $7.95 | $12.7 | +60% |
| 2024 | $12.7 | $39.0 | +206% |
| 2025 | $39.0 | $118.1 | +203% |
| 2026 YTD | $118.1 | $81.4 | -31% |
HOOD's yearly returns have swung widely, from +206% in 2024 to −58% in 2022. It's down 31% so far in 2026.
NMR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.12 | $5.22 | +2% |
| 2021 | $5.22 | $4.43 | -15% |
| 2022 | $4.43 | $3.68 | -17% |
| 2023 | $3.68 | $4.51 | +23% |
| 2024 | $4.51 | $5.86 | +30% |
| 2025 | $5.86 | $8.41 | +44% |
| 2026 YTD | $8.41 | $9.56 | +14% |
NMR has the edge over HOOD on returns for 2026, with the stronger performance.